Thalia Therapeutics Plc
Research Thalia Therapeutics Plc (THAT) on Bullrun: market cap GBX 1.15B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTHAT
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 1.15B
- Financial periodFY2025
- RevenueGBP 7.26K
- Revenue growth-0.2%
- Net income-GBP 1.21M
- Free cash flow-GBP 1.16M
- Gross margin100.0%
Valuation Snapshot
latest market cap is GBX 1.15B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 7.26K | -GBP 1.21M | -GBP 1.16M | 100.0% | 0 | GBP 1.08M | n/a | GBP 1.07M |
| FY2024 | GBP 7.28K | -GBP 1.06M | -GBP 971.50K | 100.0% | 0 | GBP 625.97K | n/a | GBP 647.65K |
| FY2023 | GBP 1.95K | -GBP 1.27M | -GBP 1.21M | 100.0% | -0.01 | GBP 1.03M | n/a | GBP 1.13M |
| FY2022 | GBP 0 | -GBP 1.03M | -GBP 828.26K | n/a | -0.01 | GBP 1.92M | n/a | GBP 2.09M |
| FY2021 | GBP 0 | -GBP 1.54M | -GBP 1.77M | n/a | -0.01 | GBP 1.78M | n/a | GBP 2.13M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | GBX 1.15B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Thalia Therapeutics Plc
Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Thalia Therapeutics Plc's market cap?
Thalia Therapeutics Plc's market capitalization is GBX 1.15B.
What does Thalia Therapeutics Plc do?
Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene.